SEARCH

SEARCH BY CITATION

References

  • 1
    Gabet AS,Mortreux F,Talarmin A, et al. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 2000; 19: 49544960.
  • 2
    Chiefffi PP,Chiattone CS,Feltrim EN,Alves RC,Paschoalotti MA. Coinfection by Strongyloides stercoralis in blood donors infected with human T-cell leukemia/lymphoma type 1 in Sao Paulo city, Brazil. Mem Inst Oswaldo Cruz 2000; 95: 711712.
  • 3
    Agape P,Copin MC,Cavrois M, et al. Implication of HTLV-I infection, Strongyloidiasis, and p53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphoma in an endemic area (Martiniques, West Indies). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 394402.
  • 4
    Hirata T,Uchima N,Kishimoto K, et al. Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg 2006; 74: 246249.
  • 5
    Nagai M,Kubota R,Greten TF,Schneck JP,Leist TP,Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax 11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myleopathy/tropical spastic paraparesis: Correlation with HTLV-I proviral load. J Infect Dis 2001; 183: 197205.
  • 6
    Yamano Y,Nagai M,Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 2002; 99: 8894.
  • 7
    Proietti FA,Carneiro-Proietti ABF,Catalan-Soares BC,Murphy EL. Global epidemiology of HTLV-I and associated diseases. Oncogene 2005; 24: 60586068.
  • 8
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: A report from the Lymphoma Study Group. Br J Hematol 1991; 79: 426437.
  • 9
    Yamada Y,Tomonaga M,Fukuda H, et al. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma. Japan Clinical Oncology Group Study 9303. Br J Hematol 2001; 113: 375382.
  • 10
    Tsukasaki K,Tobinai K,Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003; 77: 164170.
  • 11
    Tsuda H,Takatsuki K,Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 study group on hematological malignancy. Br J Cancer 1994; 70: 771774.
  • 12
    Taguchi H,Kinoshita KI,Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 182186.
  • 13
    Plumelle Y,Gonin C,Edouard A, et al. Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. Am J Clin Pathol 1997; 107: 8187.
  • 14
    Keiser PB,Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004; 17: 208217.
  • 15
    Zaha O,Hirata T,Uchima N,Kinjo F,Saito A. Comparison of antihelminthic effects of two doses of ivermectin on intestinal Strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother 2004; 10: 348351.
  • 16
    Carvalho EM,PortoDaFonseca A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26: 487497.
  • 17
    Porto AF,Santos SB,Muniz AL, et al. Helminthic infection down-regulates type 1 immune responses in human T cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2005; 191: 612618.
  • 18
    Newton RC,Kimpuangthip P,Greenberg S,Gam A,Neva FA. Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am J Med 1992; 92: 202208.
  • 19
    Matsumoto T,Miike T,Mizoguchi K, et al. Decreased serum levels of IgE and IgE-binding factors in individuals infected with HTLV-I. Clin Exp Immunol 1990; 81: 207211.
  • 20
    Satoh M,Toma H,Sugahara K, et al. Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)CD25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis. Oncogene 2002; 21: 24662475.
  • 21
    Park HU,Jeong JH,Chung JH,Brady JN. Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G2 arrest mediated by Chk1. Oncogene 2004; 23: 49664974.
  • 22
    Franchini G,Nicot C,Johnson JM. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003; 89: 69132.
  • 23
    Facer CA,Playfair JH. Malaria, Epstein-Barr virus, and the genesis of lymphomas. Adv Cancer Res 1989; 53: 3372.